4D Molecular Therapeutics (FDMT) Non Operating Income (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Non Operating Income of -$4000.0 for Q1 2026, down 105.97% year-over-year from $67000.0 in Q1 2025, and up 81.82% on a QoQ basis from -$22000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) has 7 years of Non Operating Income data on file, last reported at -$4000.0 in Q1 2026.
- Quarterly Non Operating Income fell 105.97% year-over-year to -$4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (changed N/A YoY) and the FY2025 annual result came in at -$37000.0, up 51.95% from the prior year.
- Non Operating Income advanced to -$4000.0 in Q1 2026 per FDMT's latest filing, from -$22000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $5.7 million in Q1 2024 and bottomed at -$1.2 million in Q4 2022.
- The 5-year median for Non Operating Income is $8500.0 (2022), against an average of $1.4 million.
- The widest annual swing landed in 2024, when Non Operating Income plunged 662.5%; it then surged 431000.0% in 2025.
- Tracing FDMT's Non Operating Income over 5 years: stood at -$1.2 million in 2022, then soared by 454.63% to $4.4 million in 2023, then tumbled by 100.48% to -$21000.0 in 2024, then fell by 4.76% to -$22000.0 in 2025, then jumped by 81.82% to -$4000.0 in 2026.
- Per Business Quant, the three latest FDMT Non Operating Income figures stand at -$4000.0 (Q1 2026), -$22000.0 (Q4 2025), and $4.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | 4D Molecular Therapeutics | 674.52 Mn | 674.52 Mn | - | -4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Sep 30, 2025 | 4.31 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -45,000.00 |
| Mar 31, 2024 | 5.74 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 3.72 Mn |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | -1.23 Mn |
| Sep 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -319,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Mar 31, 2021 | -94,000.00 |
| Dec 31, 2020 | -277,000.00 |
| Sep 30, 2020 | -21,000.00 |
| Jun 30, 2020 | -4,000.00 |
| Mar 31, 2020 | -13,000.00 |